Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design

Philippe Moreau1 Department of Hematology,University Hospital, Allée de l'Ile Gloriette, Nantes, 44093, France

Meletios A Dimopoulos2 Department of Clinical Therapeutics,National & Kapodistrian University of Athens, Stadiou 510562Athens, Greece

Kwee Yong3 Department of Hematology,University College London, London, UK

Joseph Mikhael4 Department of Medicine,Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, AZ85028, USA

Marie-Laure Risse5 Sanofi, Vitry-Alfortville, France

Gaëlle Asset6 Sanofi, Chilly-Mazarin, France

Thomas Martin7 Department of Hematology,University of California at San Francisco, San Francisco, CA, CA94143, USACorrespondence[email protected]

Your download is now in progress and you may close this window